Document Type : Original Article
Authors
- Hamed Cheraghmakani 1
- Mehrdad Afzalinezhad 2
- Monireh Ghazaeian 3
- Parham Mortazavi 2
- Narges Karimi 1
- Sahar Fallah 4
1 Department of Neurology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2 Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
3 Pharmaceutical Sciences Research Center, Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran
4 Department of Biostatistics, School of Health, Mazandaran University of Medical Sciences, Sari, Iran
Abstract
Background: Mitochondrial metabolism disruption increases neuron excitability and reduces migraine attack threshold. This study investigates whether serum fibroblast growth factor-21 (FGF-21) levels in chronic migraine relate to headache severity and response to sodium valproate treatment.
Methods: This pilot study involved 30 patients with chronic migraine treated with sodium valproate. Serum FGF-21 levels were assessed at baseline and after 12 weeks of treatment. Pain severity and disability were evaluated using visual analogue scale (VAS) and Migraine Disability Assessment (MIDAS). Paired t-test was used for the quantitative variables. The qualitative variables were evaluated using Pearson’s chi-square test and Fisher’s exact test. Moreover, correlation coefficients were calculated. A P < 0.05 was considered statistically significant.
Results: Mean age of the patients was 42.9 ± 11.3 years. There was a significant reduction in headache severity between baseline and the end of the study regarding VAS scores (8.50 ± 1.50 vs. 5.30 ± 2.20, P < 0.001). The same reduction was observed in MIDAS during the study (61.20 ± 33.20 vs. 20.31 ± 17.07, P < 0.001).
However, there was no significant changes in serum levels of FGF-21 over three months (299.53 ± 479.80 vs. 491.33 ± 456.64, P = 0.810), nor any relationship between these levels and headache severity scores (MIDAS: P = 0.658, VAS: P = 0.708).
Conclusion: The results of this study did not show a significant correlation between FGF-21 serum levels and changes in VAS and MIDAS throughout the study. Further research on various mitochondrial pathways can provide valuable insights into the migraine pathophysiology and help identify more effective biomarkers for monitoring therapeutic regimens.
Keywords
Main Subjects
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390(10100): 1211-59.
- Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386(9995): 743-800.
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33(9): 629-808.
- Nielsen CS, Knudsen GP, Steingrimsdottir OA. Twin studies of pain. Clin Genet 2012; 82(4): 331-40.
- Alloush R, Haroun M, Shalash A, El-Fawal H, Hamdy, M. Mitochondrial dysfunctions in patients with migraine. Neuroscience and Medicine, 2019; 10(4): 339-53.
- Friedman JR, Nunnari J. Mitochondrial form and function. Nature. 2014; 505(7483): 335-43.
- Reyngoudt H, Paemeleire K, Descamps B, De DY, Achten E. 31P-MRS demonstrates a reduction in high-energy phosphates
in the occipital lobe of migraine without aura patients. Cephalalgia 2011; 31(12): 1243-53. - Lodi R, Iotti S, Cortelli P, Pierangeli G, Cevoli S, Clementi V, et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull 2001; 54(4): 437-41.
- Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50(2): 466-70.
- Dahri M, Tarighat-Esfanjani A, Asghari-Jafarabadi M, Hashemilar M. Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutr Neurosci 2019; 22(9): 607-15.
- Tarighat EA, Mahdavi R, Ebrahimi MM, Talebi M, Nikniaz Z, Safaiyan A. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res 2012; 150(1-3): 42-8.
- Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 2013; 78(4): 489-96.
- Scholle LM, Lehmann D, Deschauer M, Kraya T, Zierz S. FGF-21 as a Potential Biomarker for Mitochondrial Diseases. Curr Med Chem 2018; 25(18): 2070-81.
- Gross EC, Lisicki M, Fischer D, Sandor PS, Schoenen J. The metabolic face of migraine - from pathophysiology to treatment. Nat Rev Neurol 2019; 15(11): 627-43.
- Yorns WR, Jr., Hardison HH. Mitochondrial dysfunction in migraine. Semin Pediatr Neurol 2013; 20(3): 188-93.
- Davis RL, Liang C, Sue CM. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. Neurology 2016; 86(21): 2010-5.
- Fisher FM, Maratos-Flier E. Understanding the Physiology of FGF21. Annu Rev Physiol 2016; 78: 223-41.
- Mesdjian E, Ciesielski L, Valli M, Bruguerolle B, Jadot G, Bouyard P, et al. Sodium valproate: kinetic profile and effects on GABA levels in various brain areas of the rat. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6(3): 223-33.
- Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010; 2010.
- McElroy SL, Keck PE, Pope HG, Hudson JI. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989; 50(Suppl): 23-9.
- Calabrese JR, Delucchi GA. Phenomenology of rapid cycling manic depression and its treatment with valproate. J Clin Psychiatry 1989; 50(Suppl): 30-4.
- Hu Q, Wang C, Liu F, He J, Wang F, Wang W, et al. High serum levels of FGF21 are decreased in bipolar mania patients during psychotropic medication treatment and are associated with increased metabolism disturbance. Psychiatry Res 2019; 272: 643-8.
- Shakiba S, Ghafarpour M, Sarraf P, Ranji-Burachaloo S, Shakiba A, et al. Serum homocysteine level and lipid profile in migraine patients treated with sodium valproate. Arch Neurosci 2019; 6(1): e79504.
- Burow P, Haselier M, Naegel S, Scholle LM, Gaul C, Kraya T. The mitochondrial biomarkers fgf-21 and gdf-15 in patients with episodic and chronic migraine. Cells 2021; 10(9): 2471.
- Mozafarihashjin M, Togha M, Ghorbani Z, Farbod A, Rafiee P, Martami F. Assessment of peripheral biomarkers potentially involved in episodic and chronic migraine: A case-control study with a focus on NGF, BDNF, VEGF, and PGE2. J Headache Pain 2022; 23(1): 3.
- Gross EC, Putananickal N, Orsini AL, Vogt DR, Sandor PS, Schoenen J, et al. Mitochondrial function and oxidative stress markers in higher-frequency episodic migraine. Sci Rep 2021; 11(1): 4543.
- Lisicki M, Schoenen J. Metabolic treatments of migraine. Expert Rev Neurother 2020; 20(3): 295-302.
- He J, Zhou M, Zhao F, Cheng H, Huang H, Xu X, et al. FGF-21 and GDF-15 are increased in migraine and associated with the severity of migraine-related disability. J Headache Pain 2023; 24(1): 28.
)